John S. Stafford III Buys 24,653 Shares of Xencor, Inc. (XNCR) Stock
Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 24,653 shares of the stock in a transaction on Wednesday, October 25th. The shares were bought at an average price of $20.01 per share, with a total value of $493,306.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Xencor, Inc. (XNCR) traded up 1.31% on Friday, hitting $20.04. The stock had a trading volume of 203,466 shares. The company has a 50-day moving average price of $22.65 and a 200 day moving average price of $22.36. The firm’s market cap is $940.40 million. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. The firm had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. Equities analysts forecast that Xencor, Inc. will post ($1.17) earnings per share for the current fiscal year.
A number of research analysts have issued reports on the company. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a research note on Monday. Canaccord Genuity set a $36.00 price objective on Xencor and gave the company a “buy” rating in a research note on Monday. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $28.00.
Institutional investors have recently bought and sold shares of the company. Emory University acquired a new stake in shares of Xencor in the 2nd quarter worth $1,491,000. State of Wisconsin Investment Board acquired a new stake in shares of Xencor in the 2nd quarter worth $612,000. Goldman Sachs Group Inc. boosted its position in shares of Xencor by 50.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,439 shares of the biopharmaceutical company’s stock worth $6,277,000 after purchasing an additional 87,599 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Xencor by 10.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 219,458 shares of the biopharmaceutical company’s stock worth $5,250,000 after purchasing an additional 19,921 shares in the last quarter. Finally, TD Asset Management Inc. boosted its position in shares of Xencor by 9.3% in the 2nd quarter. TD Asset Management Inc. now owns 81,769 shares of the biopharmaceutical company’s stock worth $1,726,000 after purchasing an additional 6,963 shares in the last quarter. 76.85% of the stock is owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.